MiR-204 regulates type 1 IP(3)R to control vascular smooth muscle cell contractility and blood pressure

miR-204通过调控1型IP(3)R来控制血管平滑肌细胞收缩性和血压。

阅读:1

Abstract

MiR-204 is expressed in vascular smooth muscle cells (VSMC). However, its role in VSMC contraction is not known. We determined if miR-204 controls VSMC contractility and blood pressure through regulation of sarcoplasmic reticulum (SR) calcium (Ca(2+)) release. Systolic blood pressure (SBP) and vasoreactivity to VSMC contractile agonists (phenylephrine (PE), thromboxane analogue (U46619), endothelin-1 (ET-1), angiotensin-II (Ang II) and norepinephrine (NE) were compared in aortas and mesenteric resistance arteries (MRA) from miR-204(-/-) mice and wildtype mice (WT). There was no difference in basal systolic blood pressure (SBP) between the two genotypes; however, hypertensive response to Ang II was significantly greater in miR-204(-/-) mice compared to WT mice. Aortas and MRA of miR-204(-/-) mice had heightened contractility to all VSMC agonists. In silico algorithms predicted the type 1 Inositol 1, 4, 5-trisphosphate receptor (IP(3)R1) as a target of miR-204. Aortas and MRA of miR-204(-/-) mice had higher expression of IP(3)R1 compared to WT mice. Difference in agonist-induced vasoconstriction between miR-204(-/-) and WT mice was abolished with pharmacologic inhibition of IP(3)R1. Furthermore, Ang II-induced aortic IP(3)R1 was greater in miR-204(-/-) mice compared to WT mice. In addition, difference in aortic vasoconstriction to VSMC agonists between miR-204(-/-) and WT mice persisted after Ang II infusion. Inhibition of miR-204 in VSMC in vitro increased IP(3)R1, and boosted SR Ca(2+) release in response to PE, while overexpression of miR-204 downregulated IP(3)R1. Finally, a sequence-specific nucleotide blocker that targets the miR-204-IP(3)R1 interaction rescued miR-204-induced downregulation of IP(3)R1. We conclude that miR-204 controls VSMC contractility and blood pressure through IP(3)R1-dependent regulation of SR calcium release.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。